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Background: Knee osteoarthritis (OA) is a mechanically driven disease, and it is suggested that medial tibiofemoral
knee-joint load increases with pharmacologic pain relief, indicating that pharmacologic pain relief may be positively
associated with disease progression. Treatment modalities that can both relieve pain and reduce knee-joint load
would be preferable. The knee-joint load is influenced by functional alignment of the trunk, pelvis, and lower-limb
segments with respect to the knee, as well as the ground-reaction force generated during movement. Neuromuscular
exercise can influence knee load and decrease knee pain. It includes exercises to improve balance, muscle activation,
functional alignment, and functional knee stability. The primary objective of this randomized controlled trial (RCT) is
to investigate the efficacy of a NEuroMuscular EXercise (NEMEX) therapy program, compared with optimized analgesics
and antiinflammatory drug use, on the measures of knee-joint load in people with mild to moderate medial
tibiofemoral knee osteoarthritis.
Method/Design: One hundred men and women with mild to moderate medial knee osteoarthritis will be
recruited from general medical practices and randomly allocated (1:1) to one of two 8-week treatments, either
(a) NEMEX therapy twice a week or (b) information on the recommended use of analgesics and antiinflammatory drugs
(acetaminophen and oral NSAIDs) via a pamphlet and video materials. The primary outcome is change in knee load
during walking (the Knee Index, a composite score of the first external peak total reaction moment on the knee joint
from all three planes based on 3D movement analysis) after 8 weeks of intervention. Secondary outcomes include
changes in the external peak knee-adduction moment and impulse and functional performance measures, in addition
to changes in self-reported pain, function, health status, and quality of life.
Discussion: These findings will help determine whether 8 weeks of neuromuscular exercise is superior to optimized
use of analgesics and antiinflammatory drugs regarding knee-joint load, pain and physical function in people with mild
to moderate knee osteoarthritis.
Trial registration: ClinicalTrials.gov Identifier: NCT01638962 (July 3, 2012).
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Knee osteoarthritis (OA) is a common chronic joint dis-
ease leading to pain and loss of physical function, result-
ing in reduced quality of life [1]. About one third of people
with knee OA will experience progression to more-
advanced disease [2], which is the leading indication for
knee-replacement surgery. In western countries, the Age-
Standardized Incidence Rates for total knee replacement
are crudely 150 per 100,000 person-years [3]. However,
the majority of patients do not progress and are managed
in primary health care.
Clinical guidelines advocate nondrug treatments as
first-line treatment for knee OA [4-6]. These include in-
formation, exercise, and weight loss, and are preferred
for their anticipated negligible adverse effects while still
having relevant clinical efficacy. Despite this, both over-
the-counter and prescribed pain-reducing pharmacologic
agents (analgesics and antiinflammatory agents) are widely
and more commonly used treatments for knee OA in
primary health care [7]. Although these are preferred
for their ease of application and dose-dependent pain-
relieving effect [8], they also have dose-dependent ad-
verse effects [9-11].
Biomechanical factors play a role in symptoms and
disease progression in knee OA
After the use of analgesic agents, pharmacologic pain
relief seems to be associated with increased joint loads,
which can potentially result in disease progression [12,13].
Joint loading has a central role in symptoms and disease
progression [14], and therapies targeting mechanical load
are thus likely to be successful in the management of knee
OA. During the stance phase of walking, high loads are
applied to the medial knee compartment [15]. Some
evidence shows that the external peak knee-adduction
moment (KAM) has a significant relation to in vivo
measurement of medial compartment load [15], and
important clinical outcomes, including radiographic
OA severity [16] and knee pain [17]. One study
showed that the KAM impulse might be more sensi-
tive in discriminating between the OA severity level than
the peak KAM [18]. A novel study showed that the com-
bined peak knee moment from all three planes (Knee
Index) is sensitive enough to distinguish between pain
levels [19]. With pharmacologic and biomechanical treat-
ments, the joint load is amenable to clinically relevant
change [19-23].
The knee index is influenced by the functional align-
ment of the trunk, pelvis, and lower-limb segments with
respect to the knee during movement and the ground-
reaction force generated. Thus, it is likely that interventions,
such as neuromuscular exercise, targeting the efficiency
of lower-limb movement and muscle-activation patterns
can be effective in improving dynamic knee-joint loading[14,24], whereas interventions providing pain relief through
pharmacologically mediated pathways may be associated
with an increase in knee-joint load [12,13].
Exercise as treatment in knee injury and knee OA
NEuroMuscular EXercise (NEMEX) includes exercises to
improve balance, muscle activation, functional alignment,
and functional joint stability. Unlike conventional strength
training, neuromuscular exercise addresses the quality of
movement and emphasizes joint control in all three planes.
It has effects on knee functional performance, knee bio-
mechanics, and muscle-activation patterns of the surround-
ing knee musculature [25,26]. Neuromuscular exercise
increases functional knee stability and, in pilot studies, has
shown potential to reduce knee-joint loads and improve
cartilage matrix quality in those at risk or with mild disease
[27-29] but not in those with malaligned knees and more
advanced disease [30]. Neuromuscular exercise is used ef-
fectively for prevention and rehabilitation of anterior cruci-
ate ligament injury [31-33] rehabilitation in patients with a
meniscal tear with or without the combination of menisc-
ectomy [34,35] and in patients with moderate to severe OA
before total joint replacement [36,37]. Despite its use in
other conditions and in more-severe stages of OA, only
one study has investigated the effect of this exercise form in
early stages of knee OA: an uncontrolled pilot study con-
sisting of 13 patients with mild knee OA [27] that resulted
in a −0.8 Nm/kg (95% CI, −0.04 to -0.16) reduction (14%)
in peak KAM during one-leg rise after 8 weeks of neuro-
muscular exercise.
Pharmacologic pain relief and joint load in knee OA
Pain is a mechanism that helps to protect damaged tissue
and tissue at risk of damage. In healthy subjects, experi-
mentally induced knee pain has been shown to replicate al-
tered gait-movement strategies seen in patients with mild
knee OA (that is, reduced first peak KAM and sagittal plane
moments were seen) [38]. Studies have shown that pharma-
cologically initiated pain relief in knee OA is associated
with increased loads in KAM and sagittal knee moments
[12,17,32,39,40]. Therefore, pharmacologic pain relief, by
eliminating the protective mechanism of the pain itself
may be detrimental for knee-joint structures by increasing
knee-joint load. The most common pharmacologic pain
relief used in the management of knee OA is acetamino-
phen and nonsteroidal antiinflammatory drugs (NSAIDs).
The pain-relieving effect seen from acetaminophen and
NSAIDs is comparable with the pain-relieving effect from
a low dose (less than 12 sessions) of exercise [41,42].
Objectives
The primary objective of this study is to compare the
efficacy of a specific neuromuscular exercise program
with optimized analgesics and antiinflammatory drug
Clausen et al. Trials 2014, 15:444 Page 3 of 14
http://www.trialsjournal.com/content/15/1/444use on knee loads, as well as pain and physical func-
tion in people with mild to moderate medial tibiofemoral
knee OA.
Primary hypothesis
The first peak Knee Index during walking will be re-
duced more by neuromuscular exercise than by analgesic
use.
Secondary hypotheses
Additional measures of knee-joint loading (Knee Index,
Knee Adduction Moment (KAM) and KAM impulse)
during one-leg stands from a stool and/or during walking
will be reduced more by neuromuscular exercise com-
pared with analgesic use. Functional performance will be
significantly improved by neuromuscular exercise in com-
parison with analgesic use. Pain relief will be equivalent or
potentially superior in the group having had neuromuscu-
lar exercise.
Methods/Design
Trial design and setting
This is a single-center, unstratified (with balanced
randomization (1:1)), single‐blind, controlled, parallel‐
group study conducted in Denmark. The study protocol
conforms to the SPIRIT statement [43], and the subse-
quent reporting will follow the recommendations from
CONSORT for nonpharmacologic studies [44] (Figure 1:
Flow diagram). Participants will be recruited from gen-
eral medical practices [45] and advertisements in the local
community.
Participants
A sample of 100 patients with knee OA (including both
men and women) aged 40 to 70 years will be recruited
via primary care general practitioners (GPs) in the com-
munities of Odense and Middelfart, Denmark, and from
advertisements in local clubs, libraries, print media, and
Facebook. For a full list of inclusion and exclusion cri-
teria, see Table 1. In summary, the eligibility criteria are
selected to achieve high external validity of the study
findings by using a pragmatic trial design [46]. Patients
should have persistent knee pain in accordance with the
ACR criteria [47] and no contraindication for exercise,
NSAIDs, or x-ray, or have had leg surgery/trauma within
the last 6 months.
Procedure, randomization and allocation concealment,
and blinding
Participants will be given a short introduction to the
study and be assessed for eligibility by a GP. The GPs
will be recruited by a letter of invitation and given an
honorarium (€35) for each included participant. Partici-
pants recruited through advertisements will be assessedfor eligibility by a physiotherapist. Thereafter, the partici-
pant will be invited to a formal information meeting
with the project manager, during which the signing of an
informed-consent form, and a clinical assessment will
take place for all participants.
Eligible participants will be randomly allocated in per-
muted blocks of four to six generated a priori by our stat-
istician (RC) to either the group receiving the NEMEX
therapy (NEMEX-group) or the group receiving the anal-
gesics and NSAIDs therapy (Pharma-group). See later for
description of the two interventions. Consecutively num-
bered opaque envelopes will be opened after the partici-
pant has been tested at baseline (BC). The patient will be
informed about the allocation immediately after baseline
testing.
All outcomes will be assessed at baseline and after treat-
ment (8 weeks), and the self-reported measurements will
also be collected by mail at 12 months (see Figure 1). Out-
come assessments at baseline and after treatment will
be carried out at the motion laboratory at the Odense
University Hospital by the same assessors who will re-
main blinded to group allocation throughout the study.
Data analysis will be done in a blinded manner by the
study statistician (RC) not directly involved in the study.
Interventions
The NEMEX-KOA (NEuroMuscular Exercise–Knee Osteo
Arthritis) training program
We have applied the principles of neuromuscular train-
ing in the NEMEX-KOA training program as follows:
The training sessions consist of five parts: warming up,
functional, proprioceptive, endurance strengthening, and
cooling down. The warming-up period consists of erg-
ometer cycling, treadmill, or stepper for 10 minutes at a
”rather strenuous” level [51]. The functional part com-
prises five exercises, including neuromuscular exercises
with the key elements: core stability/postural function,
postural orientation, lower-extremity muscle strength.
The proprioceptive part comprises three exercises, with
the key elements being balance and functional stability
(Figure 2). The endurance strengthening part comprises
three exercise circuits, with the key elements of postural
and functional stability of the trunk and knee. Some of
the constructs related to muscle function, muscle tests,
and muscle training (adapted from Ericsson et al. [35])
are outlined in Table 2.
The exercises are mainly performed in a closed kinetic
chain. However, because muscle weakness of the lower ex-
tremity, particularly the quadriceps, is common in partici-
pants with OA, open kinetic chain exercises are also used
to improve muscle strength of the knee, hip and trunk
muscles. Each exercise is performed in two sets of 12 repe-
titions, with the time for rest corresponding to the dur-
ation of one set, between sets. The exercises are performed
Figure 1 Flow diagram.
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Table 1 Eligibility criteria of the EXERPHARMA-trial
Inclusion criteria
1. Compliance with the ACR criteria [47,48]
a) Risk factors: Age >40 years; female; overweight; occupation; family history of OA
b) Symptoms: persistent knee pain; brief morning stiffness; functional limitations; acute knee pain
c) Objective examination: crepitus during active movement; bony tenderness; bony enlargement;
palpable effusion; no palpable warmth; restricted movement; instability.
2. No, mild, or moderate medial knee OA defined as “No osteoarthritis”, “Doubtful narrowing of joint space and/or
possible osteophytes”, “Definite osteophytes and possible narrowing of joint space”, “Multiple osteophytes,
definite narrowing of joint space, and some sclerosis and deformity of bone ends.” This corresponds to the
modification of Kellgren and Lawrence (KL) grades 0, 1, 2, and 3, respectively [49,50]
3. Willingness to participate in exercise intervention and pharmacologic intervention
4. A maximum of 80 of 100 points in the KOOS Pain subscale (corresponding to, on average, at least mild pain)
5. BMI of less than 32
Exclusion criteria
General:
1. Difficulty complying with treatment schedule
2. Inability to fill out questionnaires
3. Inability to ambulate without assistive device
4. Problems affecting the lower extremity overriding the problems from the knee
5. Physician-determined:
6. Any condition contraindicating use of acetaminophen, NSAIDs, or exercise
7. Already taking NSAIDs or acetaminophen at doses similar to or higher than the study dose
8. Diagnosis of systemic arthritis
Radiographic:
1. Medial greater than lateral joint-space width
2. Medial knee OA of KL grade 4
Previous and planned interventions:
1. Previous ACL reconstruction or known ACL deficiency
2. Previous tibial osteotomy
3. Previous ankle, knee, or hip total joint replacement
4. Knee surgery including arthroscopy within the past 6 months
5. Steroid injection within the past 6 months
6. Knee surgery planned within the next 6 months
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focus is on the affected leg. To allow for progression, three
to four levels of difficulty are given for each exercise. Pro-
gression is made when an exercise is performed with good
sensorimotor control and good quality of performance
(based on visual inspection by the physiotherapist) and
with minimal exertion and control of the movement (per-
ceived by the participant). The cooling down part of the
training program includes walking in various ways with
emphasis on alignment, and stretching exercises for the
lower extremity muscles (10 minutes) [34,52,53].
The exercises in the five parts of the training program
are given in File 1 of the appendix. Training will take place
in groups, at one of two clinics under the supervision of
one of two experienced physiotherapists specialized in thetreatment of musculoskeletal disorders. All treating phys-
iotherapists in this study have received education in the
exercise program and the study’s data-registration process;
in addition, they are supervised by a colleague and have
regular meetings with the first author (BC) to ensure com-
pliance with the study protocol and the exercise program.
On average, about 5 to 10 participants will attend each
training session. New participants will continuously enter
the training group that is, the group will hold both novice
participants and those who have participated in a number
of the training sessions and, thus, will be more familiar
with the training. During each group-training session,
each participant will be monitored individually so that the
exercises are performed at a training level consistent with
their current level of neuromuscular function.
Figure 2 Knee alignment. (A) “Knee-over-toe-position”, that is, lower extremity well aligned with appropriate position of knee over foot. (B)
“Knee-medial to-foot-position”, that is, lower extremity not well aligned; the medial placement of the knee relative to the foot is inappropriate.
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sessions per week, each of 60 minutes. The training ses-
sions will take place in the late afternoon, because half of
the participants are anticipated to be active members of
the work force. Based on earlier studies, the intervention
period will be 8 weeks, with sessions run twice per week
(up to a maximum of 16 sessions) [52,54].
Pain monitoring during the exercise intervention
The pain-monitoring system is part of the NEMEX con-
cept [55]. Participants will report pain on a visual
analogue scale (VAS) graded from 0 to 10, in which 0 is
“no pain” and 10 is “pain as bad it could be”, before and
after each training session. Pain up to 2 on the scale is
considered “safe”; between 2 and 5 is considered “accept-
able”; and pain >5 is considered “high risk” [52,55]. “Ac-
ceptable pain” (between 2 and 5) is allowed during and
immediately after training, and increase in resting pain
compared with normal is accepted as long as the increase
has subsided to normal resting pain level at 24 hours after
the training session [22,52,55].Table 2 Constructs related to muscle function
Constructs Definitions
Muscle strength The amount of external force that a musc
Muscular endurance The ability of muscle groups to exert exte
Functional alignment Lower limb alignment during weight-bea
the second toe without tending to fall in
Functional performance
test/measures
A test that challenges muscle strength an
and the trunk (for example, various knee
(for example, measuring length, number o
Closed kinetic chain exercise Weight-bearing exercise with distally situa
and where the distal segment is usually f
Open kinetic chain exercise Non weight-bearing exercise, with a prox
single joint, and where the distal segmenCompliance with the exercise therapy program
All possible effort will be made to enhance compliance
with the program, such as explaining the importance of
adhering to the exercises to receive effect.
Registration of adherence, exertion, and pain in the
NEMEX group
At every exercise session, the physiotherapist will record,
in an exercise diary, the date for each attended session
(to determine the number of sessions), the individual
level for each exercise (to determine progression from
level to level), perceived exertion (Borg RPE CR-10 [51]),
and current pain (VAS). If participants perceive un-
acceptable pain during or after exercise, the supervising
physiotherapist will assist in decreasing the level of the
exercises.
Rescue medication in the NEMEX group
Although we do not recommend it, participants are
allowed over-the-counter and prescribed pharmacologic
pain relief as rescue medication. Use of rescue medicinele can exert
rnal force for many repetitions or successive exertions
ring. A correct functional alignment means that the knee is lined up over
wards/medially during knee flexion (Figure 2)
d postural control or dynamic joint stabilization in the lower extremities
bending tests). A physical performance test is a quantitative test
f repetitions, seconds) that evaluates the prerequisite for function
ted axis of motion and a movement occurring in several joints,
ixed to a supporting surface (for example, a squat)
imally situated axis of motion and a movement occurring at a
t is free to move (e.g., extension of the knee in a sitting position)
Clausen et al. Trials 2014, 15:444 Page 7 of 14
http://www.trialsjournal.com/content/15/1/444will be noted by the participants in their individual




Knee biomechanics (mean ±95% CI): 0, 8 weeks
Knee index, during gait
Secondary end points:
Knee biomechanics (mean ±95% CI): 0, 8 weeks
Knee Index, during one-leg rise
Peak Knee Adduction Moment, during gait
Peak Knee Adduction Moment, during one-leg rise
Knee Adduction Moment Impulse, during gait
Knee Adduction Moment Impulse, during one-leg rise
Functional performance test (mean ±95% CI): 0, 8 weeks
Maximum one-leg rises from stoolPharmacologic pain-relief (Pharma) group
Participants in the Pharma group will receive informa-
tion on how best to use acetaminophen and oral
NSAIDs, in doses consistent with Danish guidelines [4].
The information will be provided by a pamphlet and a
video outlining the recommended use of mild analgesics
and antiinflammatory drugs (that is, acetaminophen and
oral NSAIDs). Osteoarthritis Research Society Inter-
national (OARSI), European League Against Rheuma-
tism (EULAR), and Danish guidelines recommend
starting treatment with acetaminophen up to 4 g/daily in
three to four doses. If acetaminophen proves to be inad-
equate, the treatment can be supplemented with an oral
NSAID [4-6]. For participants with an increased risk of
gastrointestinal problems, a mucosal protector will be
recommended in addition to the NSAID. Participants
will be encouraged to take their medication according to
need and can change the medication when their pain
levels alter.
Treatment in the Pharma group is designed to reflect
recommended use of acetaminophen and over-the-
counter NSAIDs. Therefore, participants will have to pay
for their own drugs. In Denmark, where the trial will
take place, the cost for full-dose (4,000 mg daily for
8 weeks) use of acetaminophen will be €30 (at 2013
prices), and for full-dose (2,400 mg daily for 6 weeks)
NSAIDs (for example, Ibuprofen), the cost will be €30. If
participants do not have sufficient pain relief from over-
the-counter acetaminophen, the information pamphlet
will inform them to contact their GPs, who may pre-
scribe additional NSAIDs. The GP has been instructed
that the Pharma group in this study is to use either acet-
aminophen alone or acetaminophen in combination with
NSAIDs.Maximum number of knee-bendings in
30-second test
One-leg hop for distance test
Patient-reported outcomes:
Mean KOOS subscale scores (mean ±95% CI): 0, 8, 52 weeks
Pain
Other symptoms
Activities of Daily Living (ADLs)
Sport and Recreation Function
Knee-related Quality of Life (QOL)
Activity level:
UCLA activity score, change from baseline 0, 8, 52 weeks
Pain level:
Pain-level text messages, intensity (0–4) During
treatmentMonitoring during the treatment period
Both groups will be contacted by Short Message Service
(text messaging) on their mobile phones twice per week
(in total, 16 assessments) and will be asked to answer
three questions: 1. “What is your level of pain right
now?” (0 = none, 1 =mild, 2 =moderate, 3 = severe and
4 = extreme); 2. “Did you use any pain-relieving drug
yesterday?” (yes/no); 3. “Have you had any adverse event
since the last text message?” (yes/no), and if yes to Ques-
tion 3, the participant will be contacted by the first au-
thor (BC) to identify the nature of the adverse event.
With this monitoring, we will be able to know how pain
changes during the treatment period, how often anal-
gesic drugs are used during the treatment period, and if
and when adverse events occur during the treatmentperiod. Text messaging has been successfully used previ-
ously to evaluate real-time back pain [56].
Outcome measures
Outcome measures are listed in Table 3.
Primary outcome
The primary outcome is change in knee load during
walking. In this article, the term knee load refers to first
peak Knee Index, a surrogate measure calculated to esti-
mate the knee load. The primary outcome will be
between-group change in Knee Index immediately after
intervention.
External Peak joint moments in the frontal, sagittal,
and transverse plane will be used to calculate the Knee
Index during gait. The Knee Index is a surrogate for
total load across both compartments, and has been
chosen because changes in the external moment are
known to occur in the sagittal plane before and without
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plane [14,19,57]. Knee index is a novel functional vari-
able, constructed from the maximal external moments
affecting the knee in the frontal, sagittal, and transverse
planes, expressed in Figure 3 [58]. The Knee Index will
be reported normalized to height and weight.
Secondary outcomes
Biomechanical outcomes
The secondary biomechanical outcomes will be the Knee
Index during one-leg rise, first peak Knee Adduction
Moment (KAM) during gait and one-leg rise, and KAM
impulse during gait and one-leg rise. These measures
will be normalized to height and weight.
All biomechanical outcome calculations will be based on
measurements taken during gait and one-leg rise before
and after treatment by using a 3D Vicon MX movement-
analysis system with eight cameras operating at 100 Hz
(Vicon, Oxford, UK) and two AMTI force-plates (AMTI,
OR6-7, Watertown, MA, USA) embedded at floor level,
operating at 1,000 Hz. Because of hardware upgrade dur-
ing the inclusion period, the first 24 subjects will be mea-
sured with a 3D Vicon MX movement-analysis system
with six cameras operating at 100 Hz (Vicon) at both
baseline and after intervention. A technician experienced
in gait analysis and the Vicon system will attach reflective
markers that reflect infrared light according to the Vicon
Plug-in-Gait marker set and model [59,60]. Data will be
combined by using inverse dynamics to yield measures of
external joint moments and ranges of motion and calcu-
lated by Plug-In Gait software.
Functional performance measures
To avoid systematic bias due to a potential learning ef-
fect, the leg to be tested first will be randomized at the
time of each testing.
To evaluate functional performance [61], we will use three
tests that have shown evidence of validity in knee OA, in
the following order; Maximum number of one-leg rises
from a stool [62], maximum number of knee-bendings in
30 seconds [63], and one-leg hop for distance [63].
Maximum one-leg rises from a stool
This test evaluates the number of times the participant can
rise from a stool on one leg [27,62,64]. A lower number of
one-leg rises has been found to be predictive of develop-
ment of radiographic signs of OA [62]. The participant sitsFigure 3 Equation for calculating the Knee Index.on a stool (0.48 m). The participant places one foot on the
floor in a self-chosen position. One familiarization attempt
is allowed, and thereafter, the foot position may not be
changed during the test. The lifted leg is held with straight
knee, and the arms hang alongside the body. The test is to
be performed with full muscle control—that is, the sitting-
down phase should be performed at constant speed and
the rising phase is to be performed without adding arm or
trunk movement. A pause of 5 minutes is allowed between
testing the right and left leg. If the opposite (raised) leg
touches the ground, the trial is stopped, and the performed
number is noted. The number of adequately performed
rises is counted and noted [27,62]. This test will also
be recorded with 3D motion capture and video from the
right side.
Maximum number of knee-bendings in 30 seconds
This test evaluates the ability to perform fast changes be-
tween eccentric and concentric muscle force over the
knee joint, and is found to be reduced in participants with
and without radiographic OA at 20 years after meniscec-
tomy compared with healthy controls [63,65]. The partici-
pant stands on one leg with fingertip support of the index
fingers from a bar placed in front, with the foot placed on
the vertical line of a T-mark on the floor. The participant
then looks down on the horizontal line and bends his or
her knee, without bending forward from the hip, until he
or she no longer can see the horizontal line (about 30 de-
grees of knee flexion) consecutively for 30 seconds [63].
The participant will first perform practice trials for 10 sec-
onds. Thereafter, the stopwatch will be started after a
countdown from three. For each leg, the total number of
knee bends performed in 30 seconds is noted. If the op-
posite (raised) leg touches the ground, the trial is stopped,
and the performed number is noted [63]. This test will
also be recorded with 3D motion capture and video from
the front.
One-leg hop for distance
This test mimics sporting activities and demands explosive
muscle function, balance, and functional stability of the
knee, and was found feasible in participants with a mean
age of 50.3 years with and without radiographic OA at
20 years after meniscectomy [63,66,67]. The participant
stands on the leg to be tested, hops, and lands on the same
limb. The hands are placed behind the back. The partici-
pant is instructed to perform a controlled, balanced landing





Aastrands test 0, 8 weeks
Observer-reported outcomes
Performance in exercise group




SF-36 acute v. 1.0 (95% CI) 0, 8, 52 weeks
Health economic evaluation
EQ-5D v. 1.0 (95% CI) 0, 8, 52 weeks
Adverse events
Adverse events questionnaire, change from baseline 0, 8 weeks





Drug use diary, amount, intensity, and type 8 weeks
Drug use text message, numbers During
treatment
Assessment of treatment
Global perceived effect (GPE) 8, 52 weeks
Patient Acceptability Symptom State (PASS) 8, 52 weeks
Treatment since end of study treatment
Treatment questionnaire, amount, type, and duration 52 weeks






1 Doubtful narrowing of joint space and/or possible
osteophytes
2 Definite osteophytes and possible narrowing of joint
space
3 Multiple osteophytes, definite narrowing of joint space,
and some sclerosis and deformity of bone ends
4 Large osteophytes, marked narrowing of joint space,
severe sclerosis, and definite deformity of bone ends
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until the landing position has been recorded by the tester.
Failure to stand still for 2 to 3 seconds results in a dis-
qualified hop. The distance hopped is measured in centi-
meters from the toe at push-off to the heel where the
participant lands. Participants will perform one practice
trial and then three test trials. If the participant improves
more than 10 cm between the second and third hops, an
additional hop is performed [63,66]. Shoes will be worn.
The best trial will be used. Symmetry index will be calcu-
lated as (injured side/uninjured side) × 100 [66].
Patient-reported outcomes
The Knee injury and Osteoarthritis Outcome Score (KOOS,
www.koos.nu) [68-70] is a questionnaire that assesses self-
reported outcomes in five separate subscales: Pain, Other
symptoms, Activities of Daily Living (ADL), Sport and
Recreation Function, and Knee-related Quality of Life
(QOL), calculated as separate subscale scores ranging from
0 to 100, worst to best. For assessment of physical-activity
level, the University of California at Los Angeles (UCLA)
activity score will be used [71]. It assesses self-reported
current activity level on a scale of 1 to 10, worst to best.
Exploratory outcome measures
Exploratory outcome measures are listed in Table 4.
Aerobic capacity
Aastrands test Before the 3D movement analysis and
functional performance tests, participants will perform a
standardized warm-up session consisting of the Aastrands
test (submaximal 1-point test on a stationary bicycle) for
approximately 10 minutes. The participant cycles at
60 rpm, with the workload adjusted to target a stable heart
rate of 120 to 170 bpm. From pulse rate and workload,
the aerobic capacity will be estimated [51].
Radiographic outcomes
Classification of osteoarthritis
As a means of describing participant characteristics, the
radiographic severity will be classified according to
the Kellgren-Lawrence (KL) classification in grades 0
to 3, with grade 4 being an exclusion criterion (Table 5)
[49,50]. Radiographs of both knees will be taken, in
posterior-anterior, mediolateral directions, and patella
skyline. The posterior-anterior radiograph is taken with
the participant standing at a fixed flexion angle by using
the Synaflex frame [72]. The mediolateral radiograph is
taken with the participant standing with semiflexed knees
(~10 degrees) and the tibia kept vertical [73]. The patella
skyline radiograph is taken with the participant standing
with flexed knee (about 70 to 110 degrees), with the x-ray
beam level with the base of the patella [73].Additional patient characteristics
At screening, the participants will fill out a questionnaire
to record gender, age, weight, height, level of education,
and working, smoking, and civil status.
Health economic analyses
To perform a health economic evaluation, the partici-
pants will complete the EuroQOL (EQ-5D). EQ-5D [74]
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mobility, self-care, pain, and usual activities. The five-
domain questionnaire classifies 243 different health states
by using three levels of severity for each domain (no prob-
lems, some problems, extreme problems). The Danish
EQ-5D tariff was estimated by using the time trade-
off method in a sample of 1,332 respondents from the
Danish general population [75]. It consists of a set of
numbers that indicates the level of health-related quality
of life for each EQ-5D health state, on a scale from 1 (full
health) to 0 [dead; range, −0.624 to 1, where negative
values are valued as worse than dead] [75].
General health
The short-form health survey (SF-36) [76] is a generic
measure of health status measuring physical and mental
aspects in eight different subscales, calculated in separ-
ate subscale scores ranging from 0 to 100, worst to best.
Adverse events
Reporting of adverse events will be elicited with a non-
leading questionnaire at baseline and after treatment. All
events will be coded according to the Medical Dictionary
for Regulatory Activities, as currently required by all
regulatory authorities, including the US Food and Drug
Administration and the European Agency for the Evaluation
of Medicinal Products [77]. In addition to the questionnaire
after treatment, as previously described, adverse events
during treatment will be monitored by text messages.
Drug use
In both treatment groups, participants will complete a
drug-use diary, in which they will be asked to fill in date,
time, type, and amount of any given drug they have used
every day during the treatment period. In addition, they
can fill in the reason for taking the drug (for example,
headache or knee pain).
Treatment since end of study treatment
At the 1-year follow-up, the participants will be asked to
fill out a questionnaire on what other treatments they may
have received since the end of the study treatment.
Global rating scales
Five Global Perceived Effect (GPE) questions are used
for measuring the participants’ overall experience with
the intervention. One anchor question is used for deter-
mining Patient Acceptable Symptom State (PASS; satis-
faction with the current situation) [78]. The five GPE
questions are as follows.
Pain
How do you experience your knee pain now, com-
pared with 2 months ago when you entered the study?Answer categories: Much less, less, the same, worse, much
worse.
Symptoms
How do you experience your other knee symptoms now,
compared with 2 months ago when you entered the study?
(swelling, stiffness, decreased range of motion) Answer
categories: Much less, less, the same, worse, much worse.
ADL
How is your ability to perform activities of daily living
now, compared with 2 months ago when you entered the
study? (sitting, standing, walking, ascending/descending
stairs, putting on clothes, household activities) Answer
categories: Much better, better, the same, worse, much
worse.
Sport/Recreation
How is your ability to perform sport and recreational ac-
tivities now, compared with 2 months ago when you en-
tered the study? (running, jumping, squatting, kneeling,
twisting/pivoting on injured knee) Answer categories:
Much better, better, the same, worse, much worse.
QOL
How much do your knee problems affect your quality of
life now, compared with 2 months ago when you entered
the study? (trust in your knee, changed lifestyle, how often
you think of your knee, and so on) Answer categories:
Much less, less, the same, worse, much worse.
The anchor question for determining PASS is as follows:
When you take into consideration your daily life, your
pain and other symptoms, and your impairment and qual-
ity of life, do you then consider your current situation sat-
isfactory? Answer categories: yes, no.
Sample size
For a two-sample pooled t test of a normal mean differ-
ence with a two-sided significance level of 0.05, assum-
ing a common standard deviation of 0.8 Nm/BW ×HT%
[19], a sample size of 42 participants per group is re-
quired to obtain a power of at least 80% to detect a dif-
ference between the means of first peak Knee Index of
0.5 Nm/BW ×HT% (corresponding to a 27% difference
in means) [19]. To make up for some attrition during
the trial period, we have decided to include 100 partici-
pants in total (randomized 1:1). If the drop-out rate
proves to be lower, the number of recruited participants
will be adjusted accordingly but will not be below 84.
Data and statistical analysis
Data will be analyzed in a blinded manner. Main compara-
tive analyses between groups will be performed by using a
modified intention-to-treat analysis (all cases with available
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ences and 95% confidence intervals will be estimated with
a general linear model in which the participant’s baseline
score is entered as a covariate [79]. We will also perform a
per-protocol analysis as appropriate: In the NEMEX group,
we define the per-protocol population as those participants
who participated in at least 12 exercise sessions (that is,
good compliance). In the Pharma group, we define the
per-protocol population as those participants who used
pharmacologic pain relief (acetaminophen or equivalent
dose of NSAID) for more than 2,000 mg/daily on at least
28 days (that is, good compliance) during Pharma inter-
vention. If fewer than 12 patients from each intervention
group can be categorized as having good compliance, we
will dichotomize the populations and compare the halves
with the better compliance.
For binary response variables (for example, text-messaging
question; drug use and adverse events), statistical signifi-
cance will be tested by logistic regression analysis with
treatment as the fixed-factor covariate.
Data interpretation
To minimize bias, we have a priori decided how to in-
terpret the possible variation in follow-up data scenarios:
(a) If knee-joint load is reduced more in the NEMEX
group compared with the Pharma group, then NEMEX
is the preferred treatment; (b) if knee-joint load is re-
duced more in the Pharma group compared with the
NEMEX group, then Pharma is the preferred treatment;
or (c) if knee-joint load does not differ between the two
treatment groups, the treatment associated with the
greatest pain relief, functional improvement, and the
fewest adverse events will be favored.
Ethics and registration
This study is approved by the regional Committee for
Medical Research Ethics, Project-ID: S-20110153 and the
Danish Data Protecting Agency. The study is recorded at
ClinicalTrials.gov, Identifier: NCT01638962. The Danish
Medicines Agency has reviewed the protocol. The proce-
dures followed are in accordance with the ethical standards
of the responsible committee on human experimentation
(institutional and national) and with the Declaration of
Helsinki 1975, as revised in 2000. Because the intervention
involves advice on optimal use of analgesics instead of a
prescription of a specified dose, the study is considered a
nonpharmacologic study and is therefore not required to
undergo review by the Danish Medicines Agency’s external
trial unit.
Discussion
The need to develop efficacious treatment approaches for
knee OA that are capable not only of relieving symptoms
but also of slowing disease progression is an importantresearch topic and clinical objective [80]. Our study builds
on the premise that dynamic knee loading can be altered
in individuals with mild to moderate knee OA. If knee
loading can be reduced during functional weight-bearing
ADLs, structural degeneration may be slowed in addition
to achieving symptom relief. This study is, to our know-
ledge, the first RCT to compare the efficacy of two pain-
relieving treatments with very different mechanisms of
action, neuromuscular exercise and drug use, on knee load
and function in people with mild to moderate knee OA.
Strengths of the study are the rigorous method, the
pragmatic nature of the treatment delivery that takes place
in several physiotherapy clinics and the self-administered
use of pain-relieving drugs, and the reproducibility and
feasibility of the exercise program [52]. The study is de-
signed to have a high degree of external validity. The prag-
matic recruiting procedure in which patients are recruited
from GPs and advertisements in the local community is
a strength because these people are often faced with a
choice between these two treatment options.
A drawback of the pragmatic design is the inherent
risk of recruiting a heterogeneous group, thereby leading
to a negative result, even though heterogeneity is com-
mon in this clinical population.
It was recently shown that neuromuscular exercise does
not reduce KAM in patients with moderate to severe knee
OA and varus malalignment [30]. That study differs from
the current one in two central aspects: primary outcome
and patient group. In the study by Bennell et al. [30], the
primary outcome was peak KAM (reflecting medial com-
partment load, using only the frontal plane), and the
population had more-severe disease as reflected by KL
grades 2 through 4 and varus malalignment. In the current
study, the primary outcome is peak Knee Index (reflecting
joint load across both compartments in all three planes),
and the population had moderate to no radiographic knee
OA (KL 0 to 3).
This study tests two different modalities of pain relief
that might be important for the change in knee-joint load.
Pharmacologic pain relief might increase joint loads
[12,13], and neuromuscular exercise might decrease knee-
joint load.
The primary outcome of the Knee Index is a surrogate
measure for the combined external load across both med-
ial and lateral knee compartments. It should be noted that
two participants can have the same absolute value on the
Knee Index and have different medial compartment load,
if, for instance, the relative contribution of the knee-
adduction moment is different. The patient-reported out-
come measures used in this study are chosen on the basis
of their validity, feasibility, and relevance for the study
aim [68-71,74-77].
In the current study, the BMI cutoff of 32 or more was
chosen for two reasons: to prevent difficulties of marker
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clude the increased risk of soft-tissue movement artefacts
[81]. Finally, weight loss before exercise maybe the more
appropriate approach for the obese population.
To ensure a standardized recruitment procedure by all
of the GPs and via advertisements, information meetings
will be conducted before starting the recruiting process.
The recruitment procedure is kept as simple as possible
and consists of a standardized case-record form, which
the GP is to complete and send to the project manager
(BC). The recruitment through advertisements follows
the same standardized case-report form that is com-
pleted and checked by a physician. The case-report form
is designed to take no more than 5 minutes to complete.
To ensure adherence with the standardized exercise
protocol from all participating physiotherapists, attend-
ance at a 2-day course on OA knowledge and neuromus-
cular exercise is compulsory before study commencement.
In addition, each physiotherapist will have conducted a
few pilot exercise sessions together with the project man-
ager (BC) to further ensure compliance with the exercise
protocol across the participating physiotherapy clinics.
During intervention and enrollment of participants, a
weekly update email containing information on screened
and recruited participants will be sent to all collaborators
(GPs, physiotherapists, and chiropractors performing the
radiographs). If recruitment slows, a dialogue with the
relevant individual will be opened.
In addition, the study is adequately powered for the
primary outcome measure, and our recruitment strategy
will result in a sample typical of primary care. This trial,
evaluating the possible modifying effects of a neuromus-
cular exercise program on joint load in people with mild
to moderate knee OA, will improve our understanding
of how neuromuscular exercise and advice on drug use af-
fects knee-joint loads, self-reported outcomes, and func-
tional performance.
Trial status
The study is currently recruiting patients; about 45
participants have currently been enrolled and tested
at baseline.
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